New Location

Posted in: News & Events

AndroScience Corp has relocated. We’re now in the North County region of San Diego in beautiful Solana Beach, California.

Our new address:

AndroScience Corporation

265 Santa Helena, Suite 212
Solana Beach, CA 92075

Results of ASC-J9-202 Phase 2B Clinical Study

Posted in: News & Events
AndroScience Corporation announces compelling (successful) results of a pivotal clinical trial investigating ASC-J9, the first of a novel class of compounds targeting androgen function for the topical treatment of acne vulgaris in men and women.

AndroScience Corporation Awarded A $3.8 Million, 3-Year Milestone-Driven, Cooperative Translational Research Grant from the NIH To Develop An Oral Treatment for Spinal Bulbar Muscular Atrophy (Kennedy’s Disease)

Posted in: News & Events

SAN DIEGO, CA – January 25, 2011 – AndroScience Corp. (ASC), based in San Diego, California, announced receiving a $3.8 Million, 3-year milestone-driven, cooperative translational research grant from the National Institute of Neurological Disorders and Stroke (NINDS) of the National Institutes of Health (NIH).  Through a joint research effort with the Neurogenetics Branch of the NINDS, ASC will use the funding to pursue development of an oral drug treatment for spinal and bulbar muscular atrophy (SBMA) or Kennedy’s Disease, a rare hereditary neurodegenerative disease, which currently has no approved drug available to patients.  Key pathological features of SBMA include progressive motor neuropathy and androgen insensitivity syndrome caused by a distinctive mutation within the androgen receptor (AR) gene.  ASC has developed a unique platform of therapeutic small molecule drugs, which selectively and potently enhance degradation of the AR protein, termed AR degradation enhancers (ARD enhancers).


AndroScience Corporation forms Strategic Alliance with Taiwan based Orient Europharma to Develop Novel Topical Acne Therapeutic

Posted in: News & Events
San Diego, CA May 20, 2010, AndroScience Corporation (ASC) announced today the forming of a strategic partnership with Orient Europharma Co. Ltd. (OEP) of Taiwan. The collaborative agreement centers on the clinical development and commercialization of ASC’s lead therapeutic candidate, ASC- J9® as a topical anti-acne product. Under terms of the agreement OEP is responsible for clinical study expenses related to an ASC-J9® phase IIb multi center trial in acne vulgaris. Scheduled to commence in September 2010, the 180 patients, double-blinded, placebo controlled efficacy study will be jointly conducted at clinical sites in Taiwan and the USA.

AndroScience Corporation Announces Phase 2a Study Results on ASC-J9® for the Treatment of Acne

Posted in: News & Events
San Diego, CA. - March 6, 2009, AndroScience Corporation (ASCTM), a developmental stage pharmaceutical company announced results of a Phase 2a dose-ranging study of their lead clinical compound for the treatment of acne.  The randomized, double-blinded, vehicle-controlled study completed in late 2008 enrolled 186 patients with acne and consisted of twice daily topical applications of ASC-J9®cream for 12 weeks to evaluate safety and ascertain preliminary efficacy.

 
Home | Corporate Overview | Product Pipeline | Science & Technology | News & Events | Contact Us | Privacy Policy